News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Furey John
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/03/2023 |
4
| Furey John (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 500,000 options to buy
@ $0 |
|
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/01/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2019 |
4
| Furey John (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 240,541 options to buy
@ $0 |
|
| 07/06/2018 |
3
| Furey John (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC |
| 04/24/2018 |
4
| Furey John (COO) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Sold 6,723 shares
@ $82.5, valued at
$554.6k
Exercised 6,723 options to buy
@ $49.74, valued at
$334.4k
|
|
| 04/19/2018 |
4
| Furey John (COO) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Sold 2,277 shares
@ $82.5, valued at
$187.9k
Sold 11,000 shares
@ $82.53, valued at
$907.8k
Exercised 2,277 options to buy
@ $49.74, valued at
$113.3k
Exercised 11,000 options to buy
@ $49.74, valued at
$547.1k
|
|
| 04/16/2018 |
4
| Furey John (COO) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Sold 20,000 shares
@ $77.51, valued at
$1.6M
Exercised 20,000 options to buy
@ $49.74, valued at
$994.8k
|
|
| 01/22/2018 |
4
| Furey John (COO) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $50.55, valued at
$1.8M
Granted 17,500 restricted stock units
@ $0 |
|
| 01/22/2018 |
4
| Furey John (COO) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Bought 18 shares
@ $73.48, valued at
$1.3k
Sold 18 shares
@ $46.33, valued at
$833.9 |
|
| 12/05/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 12/05/2016 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
|
|